company background image
LUNG logo

Pulmonx NasdaqGS:LUNG Stock Report

Last Price

US$9.27

Market Cap

US$351.1m

7D

-1.3%

1Y

-15.5%

Updated

28 Mar, 2024

Data

Company Financials +

Pulmonx Corporation

NasdaqGS:LUNG Stock Report

Market Cap: US$351.1m

LUNG Stock Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases.

LUNG fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Pulmonx Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pulmonx
Historical stock prices
Current Share PriceUS$9.27
52 Week HighUS$14.84
52 Week LowUS$7.75
Beta0.60
1 Month Change-8.40%
3 Month Change-27.29%
1 Year Change-15.50%
3 Year Change-80.69%
5 Year Changen/a
Change since IPO-76.42%

Recent News & Updates

Pulmonx: Revisiting Thesis Following Management Change

Mar 26

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Feb 23
Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Recent updates

Pulmonx: Revisiting Thesis Following Management Change

Mar 26

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Feb 23
Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Aug 01
Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Nov 08
Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M

Aug 02

Pulmonx: Interesting Technology But Struggling With Adoption

Jul 02

These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Feb 28
These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Earnings Update: Here's Why Analysts Just Lifted Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$62.20

Mar 04
Earnings Update: Here's Why Analysts Just Lifted Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$62.20

Have Insiders Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares?

Feb 05
Have Insiders Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares?

Shareholder Returns

LUNGUS Medical EquipmentUS Market
7D-1.3%2.2%0.4%
1Y-15.5%13.3%28.8%

Return vs Industry: LUNG underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: LUNG underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is LUNG's price volatile compared to industry and market?
LUNG volatility
LUNG Average Weekly Movement8.0%
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: LUNG's share price has been volatile over the past 3 months.

Volatility Over Time: LUNG's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995279Steve Williamsonhttps://pulmonx.com

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves.

Pulmonx Corporation Fundamentals Summary

How do Pulmonx's earnings and revenue compare to its market cap?
LUNG fundamental statistics
Market capUS$351.08m
Earnings (TTM)-US$60.84m
Revenue (TTM)US$68.68m

5.2x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUNG income statement (TTM)
RevenueUS$68.68m
Cost of RevenueUS$17.92m
Gross ProfitUS$50.75m
Other ExpensesUS$111.60m
Earnings-US$60.84m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin73.90%
Net Profit Margin-88.60%
Debt/Equity Ratio31.5%

How did LUNG perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.